INSIGHTS ON SOLID DOSE MANUFACTURING
-
![Bora Pharmaceuticals - Zhunan Facility Site VR Tour]( "Zhunan Facility Site VR Tour")
Zhunan Facility Site VR TourBora’s 36,000-square-meter Zhunan, Taiwan facility delivers flexible, high-quality cGMP oral solid dose manufacturing with access to major markets including North America and the EU.
-
![Esco - DFB still]( "When To Consider Material And Personnel Airlocks For Downflow Booths")
When To Consider Material And Personnel Airlocks For Downflow BoothsStrategic use of airlocks in downflow booth design enhances pressure stability and containment. A risk-based approach ensures facility integration meets rigorous safety and compliance standards.
-
![catalent minitablets thumb]( "Developing And Manufacturing Minitablets To Extend Drug Lifecycle")
Developing And Manufacturing Minitablets To Extend Drug LifecyclePharmaceutical companies should leverage oral minitablets to extend drug lifecycles, optimize dosing, and improve patient-centric solutions while overcoming manufacturing challenges.
-
![Filling Equipment]( "Don't Let Your Filling Equipment Dictate Your Drug Formulation")
Don't Let Your Filling Equipment Dictate Your Drug FormulationGravimetric powder dosing measures true mass to eliminate equipment-driven reformulation, preserving particle design and speeding clinical development.
-
Engineering Challenges Of Designing Pharmaceutical Isolators3/27/2025
Designing pharmaceutical isolators requires navigating complex engineering hurdles, from ensuring chemical compatibility to optimizing airflow and pressure. Explore the critical considerations that guarantee drug manufacturing safety and efficiency.
-
Modeling Polymer Interactions To Improve Amorphous Solid Dispersion Stability7/15/2026
Molecular dynamics modeling revealed how hydrogen bonding between PVP and Eudragit drives stable amorphous solid dispersion formation, cutting formulation screening time significantly.
-
The Future Of Pharma Packaging Trends, Technologies, And Patient-Centric Solutions4/14/2026
Pharmaceutical packaging must evolve alongside drug development to ensure stability, safety, and regulatory adherence, utilizing innovative designs to improve therapeutic outcomes and patient accessibility.
-
Cytiva's Aseptic Filling Workcell User Group1/9/2026
Discover how global collaboration among aseptic filling experts is driving innovation and improving operations.
-
The Importance Of Polymorph Screenings5/6/2026
Discover how systematic polymorph screening reduces development risk, safeguards product performance, and enables confident solid‑form selection across the drug development lifecycle.
SOLID DOSE MANUFACTURING SOLUTIONS
-
![iStock-870087778-powder]( "Powder Flow Properties & Characterization Services")
Basic Powder Flow Characterization [USP <1174>]:
A powder flow analysis is an indicator of how well formulation will release from the hopper during the tableting. It is important to know that the developed formulation is showing ‘Mass Flow’ or ‘Funnel Flow’ or ‘Rat Holing’.
Powder blend shows ‘Mass Flow’ when the entire solid bed is in motion during the discharge of material from the outlet. This is a ‘First-in-First-Out’ process. Hoppers offering ‘Mass Flow’ have steep and/or low-friction walls. This flow offers ‘No-Arching’, ‘Less Segregation’, and ‘Stable Powder Flow’.
When the hopper is not sufficiently steep and smooth enough to ensure sliding along its wall, the powder blend exhibit ‘Funnel Flow’. Such hoppers are sensitive to arching and ratholing. In this case, powder discharge from the hopper is not predictable.
-
![Sterile Mfg]( "Sterile Manufacturing Pharmaceutical Equipment And Technologies")
Recent years have shown steady growth in manufacturing sterile, high potent products in the pharmaceutical industry. Antibiotics for intravenous or intramuscular injection in powder form such as Ceftriaxone Sodium for example, need to be produced under sterile conditions.
-
![Powder Rheology Feature]( "Powder Rheology Accessory")
The Powder Rheology Accessory expands the DHR’s capabilities to powders, enabling the characterization of behaviors during storage, dispensing, processing, and end-use.
-
![Intermittent Forming, Filling And Sealing Of Blisters for Inhalation ProductsMSP pic 1]( "Intermittent Forming, Filling And Sealing Of Blisters for Inhalation Products")
Achieve commercial-scale inhalation blister manufacturing with outputs up to 2,400 cavities per minute, flexible powder dosing, and integrated containment options.
-
![GettyImages-1302287478-powder-excipient-petri-dish]( "Enhance Dissolution Rate With A Single High Performance Excipient")
Enhance dissolution and lubrication in solid oral formulations. See how this approach supports poorly soluble actives, modern manufacturing methods, and consistent performance.
